The company’s lead product candidate, PBI-0451, is a direct-acting, oral antiviral drug to treat and prevent SARS-CoV-2 infections.
Location: United States, California, Berkeley
Total raised: $250.61M
Investors 4
Date | Name | Website |
- | Foresite C... | foresiteca... |
18.11.2021 | Khosla Ven... | khoslavent... |
27.08.2021 | Y Combinat... | ycombinato... |
- | Frazier Li... | frazierls.... |
Funding Rounds 2
Date | Series | Amount | Investors |
27.12.2021 | - | $199M | - |
03.02.2021 | - | $51.61M | - |
Mentions in press and media 2
Date | Title | Description | Source |
10.01.2022 | Pardes Bioscience Nets $199M in SPAC Merger | Another one of San Diego’s promising young biotechs has gone public via Wall Street’s SPAC merger ro... | sdbj.com/n... |
27.12.2021 | Carlsbad’s Pardes Biosciences nets $199M to keep pace in COV... | Carlsbad startup Pardes Biosciences, which has begun clinical trials for an experimental pill to tre... | sandiegoun... |